Michael M Fisher1, Gopika SenthilKumar1, Rong Hu2, Steve Goldstein3, Irene M Ong3, Margot C Miller1, Sean R Brennan1, Saakshi Kaushik1, Lindsey Abel1, Kwangok P Nickel1, Gopal Iyer1, Paul M Harari1, Randall J Kimple1, Andrew M Baschnagel4. 1. Department of Human Oncology, University of Wisconsin Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin. 2. Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 3. Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin. 4. Department of Human Oncology, University of Wisconsin Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin. Electronic address: baschnagel@humonc.wisc.edu.
Abstract
PURPOSE: We examined the capacity of the pan-fibroblast growth factor receptor (FGFR) inhibitor AZD4547 to augment radiation response across a panel of head and neck squamous cell carcinoma (HNSCC) cell lines and xenografts. METHODS AND MATERIALS: FGFR1, FGFR2, and FGFR3 RNA in situ hybridization expression was assessed in a cohort of HNSCC patient samples, cell lines, and patient-derived xenografts (PDXs). In vitro effects of AZD4547 and radiation on cell survival, FGFR signaling, apoptosis, autophagy, cell cycle, and DNA damage repair were evaluated. Reverse phase protein array was used to identify differentially phosphorylated proteins in cells treated with AZD4547. In vivo tumor responses were evaluated in cell lines and PDX models. RESULTS: FGFR1, FGFR2, and FGFR3 RNA in situ hybridization were expressed in 41%, 81%, and 89% of 107 oropharynx patient samples. Sensitivity to AZD4547 did not directly correlate with FGFR protein or RNA expression. In sensitive cell lines, AZD4547 inhibited p-MAPK in a time-dependent manner. Significant radiosensitization with AZD4547 was observed in cell lines that were sensitive to AZD4547. The mechanism underlying these effects appears to be multifactorial, involving inhibition of the MTOR pathway and subsequent enhancement of autophagy and activation of apoptotic pathways. Significant tumor growth delay was observed when AZD4547 was combined with radiation compared with radiation or drug alone in an FGFR-expressing HNSCC cell line xenograft and PDX. CONCLUSIONS: These findings suggest that AZD4547 can augment the response of radiation in FGFR-expressing HNSCC in vivo model systems. FGFR1 and FGFR2 may prove worthy targets for radiosensitization in HNSCC clinical investigations.
PURPOSE: We examined the capacity of the pan-fibroblast growth factor receptor (FGFR) inhibitor AZD4547 to augment radiation response across a panel of head and neck squamous cell carcinoma (HNSCC) cell lines and xenografts. METHODS AND MATERIALS: FGFR1, FGFR2, and FGFR3 RNA in situ hybridization expression was assessed in a cohort of HNSCC patient samples, cell lines, and patient-derived xenografts (PDXs). In vitro effects of AZD4547 and radiation on cell survival, FGFR signaling, apoptosis, autophagy, cell cycle, and DNA damage repair were evaluated. Reverse phase protein array was used to identify differentially phosphorylated proteins in cells treated with AZD4547. In vivo tumor responses were evaluated in cell lines and PDX models. RESULTS:FGFR1, FGFR2, and FGFR3 RNA in situ hybridization were expressed in 41%, 81%, and 89% of 107 oropharynx patient samples. Sensitivity to AZD4547 did not directly correlate with FGFR protein or RNA expression. In sensitive cell lines, AZD4547 inhibited p-MAPK in a time-dependent manner. Significant radiosensitization with AZD4547 was observed in cell lines that were sensitive to AZD4547. The mechanism underlying these effects appears to be multifactorial, involving inhibition of the MTOR pathway and subsequent enhancement of autophagy and activation of apoptotic pathways. Significant tumor growth delay was observed when AZD4547 was combined with radiation compared with radiation or drug alone in an FGFR-expressing HNSCC cell line xenograft and PDX. CONCLUSIONS: These findings suggest that AZD4547 can augment the response of radiation in FGFR-expressing HNSCC in vivo model systems. FGFR1 and FGFR2 may prove worthy targets for radiosensitization in HNSCC clinical investigations.
Authors: K Uzawa; T Ishigami; K Fushimi; T Kawata; K Shinozuka; A Kasamatsu; Y Sakamoto; K Ogawara; M Shiiba; H Bukawa; H Ito; H Tanzawa Journal: Oncogene Date: 2011-05-16 Impact factor: 9.867
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Adam D Swick; Andrew P Stein; Timothy M McCulloch; Gregory K Hartig; Irene M Ong; Emmanuel Sampene; Prashanth J Prabakaran; Cheng Z Liu; Randall J Kimple Journal: Oral Oncol Date: 2016-12-08 Impact factor: 5.337
Authors: Friederike Göke; Alina Franzen; Trista K Hinz; Lindsay A Marek; Petros Yoon; Rakesh Sharma; Maike Bode; Anne von Maessenhausen; Brigitte Lankat-Buttgereit; Antonia Göke; Carsten Golletz; Robert Kirsten; Diana Boehm; Wenzel Vogel; Emily K Kleczko; Justin R Eagles; Fred R Hirsch; Tobias Van Bremen; Friedrich Bootz; Andreas Schroeck; Jihye Kim; Aik-Choon Tan; Antonio Jimeno; Lynn E Heasley; Sven Perner Journal: Clin Cancer Res Date: 2015-05-26 Impact factor: 12.531
Authors: Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth Journal: Nucleic Acids Res Date: 2015-01-20 Impact factor: 16.971
Authors: Andrew M Baschnagel; Jacob H Elnaggar; Haley J VanBeek; Ashley C Kromke; Justin H Skiba; Saakshi Kaushik; Lindsey Abel; Paul A Clark; Colin A Longhurst; Kwangok P Nickel; Ticiana A Leal; Shuang G Zhao; Randall J Kimple Journal: Mol Cancer Ther Date: 2021-08-19 Impact factor: 6.261